Foley Hoag LLP represented Vergent Bioscience, Inc. on the deal.Vergent Bioscience, Inc. (“Vergent”), a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced a $21.5 million Series B…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
